Skip to main content

FDA places a hold on Ocugen's plan for U.S. trials of the Covid-19 vaccine Covaxin

The Malvern firm has a deal that will get it 45% of sales of the Covid-19 vaccine in the United States, if the product gets FDA approval.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.